Biogen CEO Says He 'Always Hated' Buying Late-Stage Drugs And Will Chase Early-Stage Deals
Chris Viehbacher says the company wants to digest a fast-expanding commercial organization, with the early-stage sweet spot at "DC to Phase 1B."
Biogen, the neurology-focused drugmaker, will steer its deal-making toward early-stage assets, Chief Executive Chris Viehbacher told analysts on the company's third-quarter earnings call on Wednesday. "I really always hated having to go buy assets in later stage because there's still a fair amount of risk associated with that," he said.
Early stage is the sweet spot
Asked by a Citi analyst how Biogen would deploy capital, Viehbacher called the early stage the "most capital efficient time to introduce new assets to a company." He put the "sweet spot" at "DC to Phase 1B."
He left room for exceptions. Biogen has been "fairly intentional" about acquisitions for three years, he said, and "We're not being as intentional now, but we can still be opportunistic" if something would add to an existing franchise.
He also said Biogen's ambition is at least 20 programs in early-stage development over the next few years. The company had gone three years without a single new-drug application to start human testing, he said, and has now had five this year.
Distraction as the constraint
Viehbacher said he is mindful of distraction. Four years ago Biogen's teams "only called on neurologists"; now regional teams also reach retina specialists, nephrologists and transplant nephrologists, and lupus would add dermatologists and rheumatologists.
About half of the top 150 executives joined in the last three years, he said. The company wants to digest that change before adding more.
Investors matter too. They "have waited a long time for us to grow," he said, so Biogen will be "very mindful" of investment against bottom-line growth.
Growth without the pipeline
Biogen, which sells multiple sclerosis, spinal muscular atrophy and other therapies, closed its Apellis acquisition in May. Viehbacher said the company can now grow even without its pipeline, so it could launch products on top of a growing base if trials succeed.
Chief Financial Officer Robin Kramer said the growth portfolio generated about $1.3 billion in the quarter, about 63% of core pharmaceutical revenue. Total revenue was $2.8 billion, up 11% from a year earlier. Biogen raised the low end of its 2026 adjusted earnings-per-share range to between $12.20 and $13.
Its market value was $37.3 billion in Wednesday morning trading.
The next test is lupus: Head of Development Priya Singhal said Biogen plans to disclose two late-stage studies of litifilimab in the first half of December.
Sources
- Biogen notches 3rd straight quarter of growth thanks to newer products, Apellis - BioSpace — biospace.com
- Biogen posts Q3 beat on multiple sclerosis drugs (BIIB:NASDAQ) | Seeking Alpha — seekingalpha.com
- Biogen Q3 Preview: Will Growth Products Drive an Earnings Beat? — Yahoo Finance
- Biogen Has 'Returned To Growth,' Says CEO — What To Know About Its Report — Yahoo Finance
- Biogen Crushes Earnings Estimates. As Old Blockbusters Fade, New Bets Pick Up the Slack. — Barron's